Lorus Therapeutics Announces the Appointment of a New Member of the Board of Directors
2007年7月24日 - 7:48AM
PRニュース・ワイアー (英語)
TORONTO, July 23 /PRNewswire-FirstCall/ -- Lorus Therapeutics Inc.
(TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in
the research and development of pharmaceutical products and
technologies for the management of cancer, announced today that it
has strengthened its Board of Directors with the appointment of Mr.
Herbert Abramson. Mr. Abramson has been in the investment industry
for 25 years managing portfolios for high net worth individuals. He
is a co-founder, Chairman and CEO of Trapeze Capital Corp., an
investment dealer and portfolio management company and is also
Chairman of Trapeze Asset Management Inc., an affiliated investment
counseling company, which together have over $1.6 billion under
administration. Mr. Abramson is a member of the Law Society of
Upper Canada and practiced corporate/securities law for 12 years
before going into the investment business. He is also currently
Chairman and a Director of St. Andrew Goldfields Ltd. "We are
delighted to welcome Mr. Abramson to our Board," said Dr. Aiping
Young, President and CEO of Lorus. "We believe Lorus will benefit
from his investment management and capital markets experience".
About Lorus Lorus is a biopharmaceutical company focused on the
research and development of novel therapeutics in cancer. Lorus'
goal is to capitalize on its research, preclinical, clinical and
regulatory expertise by developing new drug candidates that can be
used, either alone, or in combination with other drugs, to
successfully manage cancer. Through its own discovery efforts and
an acquisition and in-licensing program, Lorus is building a
portfolio of promising anticancer drugs. Lorus has completed one
Phase II and one Phase III clinical trial. Lorus Therapeutics Inc.
is listed on the Toronto Stock Exchange under the symbol LOR, and
on the American Stock Exchange under the symbol LRP. Forward
looking statements This press release contains forward-looking
statements within the meaning of Canadian and U.S. securities laws.
Such statements include, but are not limited to, statements
relating to: financings and corporate reorganizations, the
establishment of corporate alliances, the Company's plans,
objectives, expectations and intentions and other statements
including words such as "continue", "expect", "intend", "will",
"should", "would", "may", and other similar expressions. Such
statements reflect our current views with respect to future events
and are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by us are inherently subject to significant
business, economic, competitive, political and social uncertainties
and contingencies. Many factors could cause our actual results,
performance, achievements or the transactions described in this
press release to be materially different from any future results,
performance, achievements or transactions described in this press
release, if at all, that may be expressed or implied by such
forward-looking statements, including, among others: the progress
of negotiations; our ability to obtain regulatory, securityholder
and other approvals; our ability to obtain the capital required for
research and operations; the inherent risks in early stage drug
development including demonstrating efficacy; development time/cost
and the regulatory approval process; the progress of our clinical
trials; our ability to find and enter into agreements with
potential partners; our ability to attract and retain key
personnel; changing market conditions; and other risks detailed
from time-to-time in our ongoing quarterly filings, annual
information forms, annual reports and annual filings with Canadian
securities regulators and the United States Securities and Exchange
Commission. Should one or more of these risks or uncertainties
materialize, or should the assumptions set out in the section
entitled "Risk Factors" in our filings with Canadian securities
regulators and the United States Securities and Exchange Commission
underlying those forward-looking statements prove incorrect, actual
results may vary materially from those described herein. These
forward-looking statements are made as of the date of this press
release and we do not intend, and do not assume any obligation, to
update these forward-looking statements, except as required by law.
We cannot assure you that such statements will prove to be accurate
as actual results and future events could differ materially from
those anticipated in such statements. Investors are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein. Lorus Therapeutics' recent press releases are available
through the Company's website at http://www.lorusthera.com/. For
Lorus' regulatory filings on SEDAR, please go to Sedar.com. For
SEDAR filings prior to July 10, 2007 you will find these under the
company profile for 4325231 Canada Inc. DATASOURCE: Lorus
Therapeutics Inc. CONTACT: Lorus Therapeutics Inc., Dr. Saeid
Babaei, (416) 798-1200 ext. 490,
Copyright